CoChat

The safety profile of GH replacement therapy in adults

Chipman, J. J., Attanasio, A. F., Birkett, M. A., Bates, P. C., Webb, S., Lamberts, S. W. J. · 1997 · Clinical Endocrinology
Cited by 76

The DOI matches its Crossref record.

Abstract

OBJECTIVE The benefits of GH replacement in GH‐deficient adult patients are becoming accepted but the safety profile continues to be defined. The GH deficiency in adults may have arisen in either childhood or during adult life and these two groups differ with regard to history of disease. The aim of the present report was to study differences in safety profile between these two groups during long‐term replacement therapy with recombinant human GH (hGH). Possible factors which placed a patient at risk of experiencing an adverse event were also examined. PATIENTS AND DESIGN GH‐deficient adult patients were randomized into two study protocols, differing only in age of onset of the GH deficiency syndrome. There were 98 patients with adult‐onset and 67 patients with childhood‐onset GH deficiency. Each study consisted of a 6‐month double‐blind placebo‐controlled phase followed by an open‐label hGH treatment phase. Glucose tolerance, incidence of treatment‐emergent adverse events and relationship to IGF status were studied throughout the 36 months of treatment. RESULTS Human growth hormone‐related adverse events were reported less commonly in childhood‐onset patients compared with adult‐onset patients. Adult‐onset patients who continued into the open‐label therapy phase reported an increased incidence of arthralgia, myalgia and paraesthesia. There were significant increases in fasting glucose with hGH therapy but values remained within the normal range. Hypertension was reported in 7.7% of adult‐onset patients at 18 months of hGH, which was within the expected prevalence for the number of patients, but was not reported for any childhood‐onset patients. Only in adult‐onset patients were sufficient adverse events reported to enable analysis of risk factors. Patients reporting hGH‐related adverse events were significantly heavier and, therefore, received more hGH. There was a significantly greater increase in IGF‐I and IGFBP‐3 in the first month in patients who experienced hGH‐related adverse events compared with those who did not. CONCLUSION The risks of replacement therapy with hGH in GH‐deficient adults varied with pathogenesis of disease; hGH‐related adverse events occurred more frequently in patients with adult‐onset compared with those with childhood‐onset GH deficiency. In the adult‐onset patients there was an increased risk of adverse events in heavier patients and those who had the greatest increases in IGF‐I and IGFBP‐3 at 1 month of therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1046/j.1365-2265.1997.1660984.x

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 76

Metadata

Authors
Chipman, J. J., Attanasio, A. F., Birkett, M. A., Bates, P. C., Webb, S., & Lamberts, S. W. J.
Venue
Clinical Endocrinology
Publisher
Wiley
Published
1997-04
Volume
46
Issue
4
Pages
473-481
ISSN
  • 0300-0664 (ISSN-L)
  • 1365-2265
OpenAlex
W1990524920
Cited by
76
References
0
FWCI
3.76
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The safety profile of GH replacement therapy in adults. https://app.cochat.ai/papers/10.1046/j.1365-2265.1997.1660984.x
The paper
Chipman, J. J., Attanasio, A. F., Birkett, M. A., Bates, P. C., Webb, S., & Lamberts, S. W. J. (1997). The safety profile of GH replacement therapy in adults. Clinical Endocrinology. https://doi.org/10.1046/j.1365-2265.1997.1660984.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.